Predictive value of abnormal expression of MPHOSPH9 in reintervention after high intensity focused ultrasound treatment of uterine fibroids

Jing Wang, Yingjie Xie, Chaoqiang Zeng, Cheng Zeng, Lin Nie, Yang Yang
In: Journal of Obstetrics and Gynaecology Research · 2025 · vol. 51(1) , pp. e16205 · doi:10.1111/jog.16205 · PMID:39780408 · W4406191413
article OA: bronze CC0
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This study evaluated whether aberrant expression of MPHOSPH9 in blood before treatment could predict the need for reintervention after high intensity focused ultrasound (HIFU) for uterine fibroids. Among 455 participants, 95 required reintervention and 360 did not; MPHOSPH9 relative expression was measured by qRT-PCR and analyzed using Cox regression over five-year follow-up. MPHOSPH9 expression was significantly higher in the reintervention group, and Cox analysis identified uterine fibroid size and high MPHOSPH9 expression as independent risk factors for postoperative reintervention. The paper’s main limitation is that it focuses on uterine fibroids after HIFU rather than directly studying mechanisms or outcomes beyond reintervention prediction. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

AIMS: Aberrantly expressed MPHOSPH9 has been reported to be associated with poor prognosis in many diseases. Previous study indicates that MPHOSPH9 is abnormally expressed in patients with uterine fibroids (UFs). This study focused on the possible prognostic value of MPHOSPH9 in UFs patients after high intensity focused ultrasound (HIFU) treatment. METHODS: A total of 455 UFs patients participated in the study, including 95 patients who needed reintervention (Reintervention group) and 360 patients who did not need reintervention (Non-reintervention group) after HIFU treatment. They volunteered blood samples before HIFU treatment. The relative expression of MPHOSPH9 was assessed by qRT-PCR. Cox regression analysis was performed to assess the prognostic value of MPHOSPH9 and risk factors of postoperative reintervention. RESULTS: The expression of MPHOSPH9 was markedly elevated in Reintervention, compared to that of the Non-reintervention group (p < 0.001). Five-year follow-up results showed that among these postoperative patients, 95 patients required reintervention and the reintervention time mainly occurred during 10-40 months after surgery. The Cox regression analysis demonstrated that UFs size (hazard ratio = 2.769, 95% confidence interval: 1.366-5.610) and the high MPHOSPH9 expression level (hazard ratio = 3.160, 95% confidence interval: 1.506-6.630) were independent risk factors for postoperative reintervention. CONCLUSIONS: The enhanced MPHOSPH9 was a potential candidate for predicting postoperative reintervention in UFs patients.
Full text 1,988 characters · extracted from oa-html · 4 sections · click to expand

Abstract

Aims Aberrantly expressed MPHOSPH9 has been reported to be associated with poor prognosis in many diseases. Previous study indicates that MPHOSPH9 is abnormally expressed in patients with uterine fibroids (UFs). This study focused on the possible prognostic value of MPHOSPH9 in UFs patients after high intensity focused ultrasound (HIFU) treatment.

Methods

A total of 455 UFs patients participated in the study, including 95 patients who needed reintervention (Reintervention group) and 360 patients who did not need reintervention (Non-reintervention group) after HIFU treatment. They volunteered blood samples before HIFU treatment. The relative expression of MPHOSPH9 was assessed by qRT-PCR. Cox regression analysis was performed to assess the prognostic value of MPHOSPH9 and risk factors of postoperative reintervention.

Results

The expression of MPHOSPH9 was markedly elevated in Reintervention, compared to that of the Non-reintervention group (p < 0.001). Five-year follow-up results showed that among these postoperative patients, 95 patients required reintervention and the reintervention time mainly occurred during 10–40 months after surgery. The Cox regression analysis demonstrated that UFs size (hazard ratio = 2.769, 95% confidence interval: 1.366–5.610) and the high MPHOSPH9 expression level (hazard ratio = 3.160, 95% confidence interval: 1.506–6.630) were independent risk factors for postoperative reintervention.

Conclusions

The enhanced MPHOSPH9 was a potential candidate for predicting postoperative reintervention in UFs patients. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interests for this article. DATA AVAILABILITY STATEMENT The data that supports the findings of this study are available in Table S1 of this article.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (31)

Source provenance

openalex
last seen: 2026-05-14T06:25:03.100642+00:00
License: CC0 · commercial use OK